Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat® Soft Mist™ Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma

2004 ◽  
Vol 37 (3) ◽  
pp. 264-272 ◽  
Author(s):  
Andrea von Berg ◽  
Prakash M. Jeena ◽  
Peter A. Soemantri ◽  
André Vertruyen ◽  
Peter Schmidt ◽  
...  
Keyword(s):  
Ipratropium Bromide ◽  
Dose Inhaler ◽  
Efficacy And Safety ◽  
Metered Dose Inhaler ◽  
Metered Dose ◽  
Children With Asthma

scholarly journals Efficacy and safety of budesonide administered by pressurized metered-dose inhaler in children with asthma

2015 ◽  
Vol 115 (6) ◽  
pp. 516-522 ◽  
Author(s):  
Eli O. Meltzer ◽  
David S. Pearlman ◽  
Gӧran Eckerwall ◽  
Tom Uryniak ◽  
Michael DePietro ◽  
...  
Keyword(s):  
Dose Inhaler ◽  
Efficacy And Safety ◽  
Metered Dose Inhaler ◽  
Metered Dose ◽  
Children With Asthma ◽  
Pressurized Metered Dose Inhaler

scholarly journals Similar Results in Children with Asthma for Steady State Pharmacokinetic Parameters of Ciclesonide Inhaled with or without Spacer

2010 ◽  
Vol 4 ◽  
pp. CMPed.S4311 ◽  
Author(s):  
H. Boss ◽  
P. Minic ◽  
R. Nave
Keyword(s):  
Active Metabolite ◽  
Day Treatment ◽  
Systemic Exposure ◽  
Dose Inhaler ◽  
Pharmacokinetic Parameters ◽  
Metered Dose Inhaler ◽  
Inhaled Corticosteroid ◽  
Open Label ◽  
Metered Dose ◽  
Children With Asthma

Background Ciclesonide is an inhaled corticosteroid administered by a metered dose inhaler (MDI) to treat bronchial asthma. After inhalation, the inactive ciclesonide is converted by esterases in the airways to active metabolite desisobutyryl-ciclesonide (des-CIC). Aim To compare the pharmacokinetic (PK) parameters of des-CIC in children after administration of therapeutic dose of ciclesonide with and without spacer (AeroChamber Plus™). Methods Open-label, 3 period, cross over, repeated dose, PK study in 37 children with mild to moderate stable asthma (age: 6–11 y; body weight: 20–53 kg). During each 7-day treatment period, ciclesonide was inhaled once in the morning: A) 160 μg MDI with spacer, B) 80 μg MDI with spacer, and C) 160 μg MDI without spacer. Serum PK parameters of ciclesonide and des-CIC were determined on Day 7 of each period. The primary PK parameters were the AUCτ and Cmax for des-CIC. Results Inhaling ciclesonide with spacer led to a dose proportional systemic exposure (AUCτ) of des-CIC (0.316 μg*h/L for 80 μg and 0.663 μg*h/L for 160 μg). The dose-normalized systemic exposure for des-CIC (based on AUCτ) was 27% higher after inhalation of ciclesonide 80 μg or 160 μg with spacer than without spacer; the corresponding Cmax values for des-CIC were, respectively, 63% and 55% higher with spacer. No clinically relevant abnormalities or adverse drug reactions were observed. Conclusions Inhalation of therapeutic ciclesonide dose with spacer led to a slight increase in the systemic exposure of des-CIC, which does not warrant dose adjustment.

Sign in / Sign up

Export Citation Format

Share Document